Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies

Journal of Nuclear Medicine

Volumn 58, Issue 12, 2017, Pages 1906-1912

  Venema, Clasina M ^a   Mammatas, Lemonitsa H ^b   Schröder, Carolina P ^a   Van Kruchten, Michel ^a   Apollonio, Giulia ^a   Glaudemans, Andor W J M ^a   Bongaerts, Alfons H H ^a   Hoekstra, Otto S ^b   Verheul, Henk M W ^b   Boven, Epi ^b   Van Der Vegt, Bert ^a   De Vries, Erik F J ^a   De Vries, Elisabeth G E ^a   Boellaard, Ronald ^a   Van Der Houven Van Oordt, Catharina W Menke ^b   Hospers, Geke A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen receptor; Breast cancer; Estrogen receptor; FDHT PET; FES PET

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; FLUORODIHYDROTESTOSTERONE F 18; FLUOROESTRADIOL F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTATIC BREAST CANCER; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SAMPLING ERROR; SENSITIVITY AND SPECIFICITY; BIOPSY; BREAST TUMOR; CELL NUCLEUS; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY IMAGING;

BIOPSY; BREAST NEOPLASMS; CELL NUCLEUS; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE BODY IMAGING;

EID: 85037081999     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.193649     Document Type: Article

References (29)

1. Blamey RW, Hornmark-Stenstam B, Ball G, et al. ONCOPOOL: a European database for 16,944 cases of breast cancer. Eur J Cancer. 2010;46:56-71.
2. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2011;24:924-931.
3. Adair FE, Herrmann JB. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg. 1946;123:1023-1035.
4. Olson KB. Fluoxymesterone (halotestin) in the treatment of advanced breast cancer. N Y State J Med. 1959;59:248-252.
5. Layfield LJ, Saria E, Mooney EE, Liu K, Dodge RR. Tissue heterogeneity of immunohistochemically detected estrogen receptor: implications for image analysis quantification. Am J Clin Pathol. 1998;110:758-764.
6. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest. 2007;87:662-669.
7. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases. Ann Oncol. 2009;20:1499-1504.
8. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587-592.
9. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799.
10. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373.
11. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437-1446.
12. 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol. 2011;38:969-978.
13. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for im-munohistochemical testing of estrogen and progesterone receptor in breast cancer. J Clin Oncol. 2010;28:2784-2795.
14. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-721.
15. Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled andro-gens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agent for prostatic cancer. J Nucl Med. 1992;33:724-734.
16. 18 F] fluoroes-tradiol. Appl Radiat Isot. 1996;47:395-399.
17. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-354.
18. 18F] fluoro-17b estradiol PET to image the estrogen receptor in vivo: the Groningen experience. Clin Nucl Med. 2016;41:844-851.
19. van Kruchten M, de Vries EG, Brown M, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013;14:e465-e475.
20. Overmoyer B, Sanz-Altamira P, Taylor RP, et al. Enobosarm: a targeted therapy for metastatic, androgen receptor positive, breast cancer [abstract]. J Clin Oncol. 2014;32:5S.
21. Traina TA, O'Shaughnessy J, Kelly CM, et al. A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patinets with advanced androgen-receptor-positive triple-negative breast cancer [abstract]. J Clin Oncol. 2014;32:5S.
22. van Kruchten M, de Vries EG, Glaudemans AW, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with meta-static breast cancer. Cancer Discov. 2015;5:72-81.
23. 18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy. Eur J Nucl Med Mol Imaging. 2017;44:500-508.
24. 18F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor targeted therapeutic GDC-0810. Clin Cancer Res. 2017;23: 3053-3060.
25. 18F-fluoro-5a-dihidrotestosterone in prostate tumors as measured by PET. J Nucl Med. 2010;51:183-192.
26. 18F]FES) in ER positive breast cancer patients. J Pharm Pharm Sci. 2007;10:256s.
27. 18F-FDHT uptake in patients with metastasized castrate resistant prostate cancer [abstract]. J Nucl Med. 2016;57(suppl 2):464.
28. Soret M, Bacharach SL, Buvat I. Partial volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.
29. 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015;42:1682-1691.